ITGAM and prostate cancer: For THP-1 cells, there was a significant increase observed with supernatants of plasma-treated over untreated prostate cancer cells for the cell surface markers CD11b, CD11c, and CD45RA (Figure 3c), pointing to increased activation of the cells.